| pubmed-article:11748787 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11748787 | lifeskim:mentions | umls-concept:C0002395 | lld:lifeskim |
| pubmed-article:11748787 | lifeskim:mentions | umls-concept:C0171023 | lld:lifeskim |
| pubmed-article:11748787 | lifeskim:mentions | umls-concept:C1707455 | lld:lifeskim |
| pubmed-article:11748787 | lifeskim:mentions | umls-concept:C1979963 | lld:lifeskim |
| pubmed-article:11748787 | lifeskim:mentions | umls-concept:C1696465 | lld:lifeskim |
| pubmed-article:11748787 | lifeskim:mentions | umls-concept:C2003903 | lld:lifeskim |
| pubmed-article:11748787 | lifeskim:mentions | umls-concept:C0205099 | lld:lifeskim |
| pubmed-article:11748787 | lifeskim:mentions | umls-concept:C0684164 | lld:lifeskim |
| pubmed-article:11748787 | pubmed:dateCreated | 2001-12-18 | lld:pubmed |
| pubmed-article:11748787 | pubmed:abstractText | The objective of this analysis was to compare the treatment-emergent central anticholinergic-like adverse events experienced during treatment with olanzapine versus placebo in patients with psychosis and/or agitation due to Alzheimer's disease (AD). In addition, changes in cognition were assessed in a subgroup of patients with mild to moderate cognitive impairment. | lld:pubmed |
| pubmed-article:11748787 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11748787 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11748787 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11748787 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11748787 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11748787 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11748787 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11748787 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11748787 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:11748787 | pubmed:issn | 0885-6230 | lld:pubmed |
| pubmed-article:11748787 | pubmed:author | pubmed-author:BymasterFF | lld:pubmed |
| pubmed-article:11748787 | pubmed:author | pubmed-author:KennedyJ SJS | lld:pubmed |
| pubmed-article:11748787 | pubmed:author | pubmed-author:TollefsonGG | lld:pubmed |
| pubmed-article:11748787 | pubmed:author | pubmed-author:TrzepaczP TPT | lld:pubmed |
| pubmed-article:11748787 | pubmed:author | pubmed-author:BreierAA | lld:pubmed |
| pubmed-article:11748787 | pubmed:author | pubmed-author:NomikosGG | lld:pubmed |
| pubmed-article:11748787 | pubmed:author | pubmed-author:GilmoreJ AJA | lld:pubmed |
| pubmed-article:11748787 | pubmed:author | pubmed-author:ZagarAA | lld:pubmed |
| pubmed-article:11748787 | pubmed:author | pubmed-author:RotelliM DMD | lld:pubmed |
| pubmed-article:11748787 | pubmed:copyrightInfo | Copyright 2001 John Wiley & Sons, Ltd. | lld:pubmed |
| pubmed-article:11748787 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11748787 | pubmed:volume | 16 Suppl 1 | lld:pubmed |
| pubmed-article:11748787 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11748787 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11748787 | pubmed:pagination | S24-32 | lld:pubmed |
| pubmed-article:11748787 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:11748787 | pubmed:meshHeading | pubmed-meshheading:11748787... | lld:pubmed |
| pubmed-article:11748787 | pubmed:meshHeading | pubmed-meshheading:11748787... | lld:pubmed |
| pubmed-article:11748787 | pubmed:meshHeading | pubmed-meshheading:11748787... | lld:pubmed |
| pubmed-article:11748787 | pubmed:meshHeading | pubmed-meshheading:11748787... | lld:pubmed |
| pubmed-article:11748787 | pubmed:meshHeading | pubmed-meshheading:11748787... | lld:pubmed |
| pubmed-article:11748787 | pubmed:meshHeading | pubmed-meshheading:11748787... | lld:pubmed |
| pubmed-article:11748787 | pubmed:meshHeading | pubmed-meshheading:11748787... | lld:pubmed |
| pubmed-article:11748787 | pubmed:meshHeading | pubmed-meshheading:11748787... | lld:pubmed |
| pubmed-article:11748787 | pubmed:meshHeading | pubmed-meshheading:11748787... | lld:pubmed |
| pubmed-article:11748787 | pubmed:meshHeading | pubmed-meshheading:11748787... | lld:pubmed |
| pubmed-article:11748787 | pubmed:meshHeading | pubmed-meshheading:11748787... | lld:pubmed |
| pubmed-article:11748787 | pubmed:meshHeading | pubmed-meshheading:11748787... | lld:pubmed |
| pubmed-article:11748787 | pubmed:meshHeading | pubmed-meshheading:11748787... | lld:pubmed |
| pubmed-article:11748787 | pubmed:meshHeading | pubmed-meshheading:11748787... | lld:pubmed |
| pubmed-article:11748787 | pubmed:meshHeading | pubmed-meshheading:11748787... | lld:pubmed |
| pubmed-article:11748787 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11748787 | pubmed:articleTitle | The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease. | lld:pubmed |
| pubmed-article:11748787 | pubmed:affiliation | Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA. jskennedy@LILLY.com | lld:pubmed |
| pubmed-article:11748787 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11748787 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:11748787 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:11748787 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:11748787 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
